Welcome to our dedicated page for Springworks Therapeutics news (Ticker: SWTX), a resource for investors and traders seeking the latest updates and insights on Springworks Therapeutics stock.
SpringWorks Therapeutics reports developments in rare-disease and oncology medicines as a healthcare company of Merck KGaA, Darmstadt, Germany. Its news centers on OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for adults with progressing desmoid tumors who require systemic treatment, and EZMEKLY® (mirdametinib) for symptomatic, inoperable NF1-associated plexiform neurofibromas.
Recurring updates include clinical data publications from the Phase 3 DeFi trial, U.S. and European regulatory actions, orphan-drug designations, product commercialization, and targeted-therapy pipeline work in solid tumors and hematological cancers. Corporate news also reflects SpringWorks' completed acquisition by Merck KGaA and related public-company status changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.